A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:2
|
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [41] De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review
    Lessa, Morgana Pinheiro Maux
    Ferreira Junior, Alexandre Soares
    Graton, Margaret
    Simon, Erin
    Ledbetter, Leila
    Onwuemene, Oluwatoyosi A.
    BLOOD REVIEWS, 2024, 66
  • [42] Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review
    Ruffer, Nikolas
    Holzer, Marie-Therese
    Bal, Lukas Can
    Melderis, Simon
    Krusche, Martin
    Huber, Tobias B.
    Koetter, Ina
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (03) : 551 - 557
  • [43] Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review
    Nikolas Ruffer
    Marie-Therese Holzer
    Lukas Can Bal
    Simon Melderis
    Martin Krusche
    Tobias B. Huber
    Ina Kötter
    Rheumatology International, 2023, 43 : 551 - 557
  • [44] How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge
    Akwaa, Frank
    Antun, Ana
    Cataland, Spero R.
    BLOOD, 2022, 140 (05) : 438 - 444
  • [45] A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Masias, Camila
    Tarawneh, Rawan
    Wu, Haiwa
    Carter, Krista
    Yang, Shangbin
    Flowers, Alcinda
    Scully, Marie
    Cataland, Spero
    BLOOD, 2019, 134
  • [46] Dysregulated autophagy in Lymphocytes hints at contribution to immune-mediated thrombotic thrombocytopenic purpura (iTTP)
    Schaller, Monica
    Milyaev, Saveliy
    Tschan, Mario Paul
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [47] Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases
    Julie Boudali
    Benjamin Hallak
    Marie Haeck
    Anne-Laure Sellier-Leclerc
    Marc Ulrich
    Paul Coppo
    Stéphanie Tellier
    François Provôt
    Journal of Nephrology, 2022, 35 : 653 - 656
  • [48] A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura
    Abou-Ismail, Mouhamed Yazan
    Zhang, Chong
    Presson, Angela P.
    Chaturvedi, Shruti
    Antun, Ana G.
    Farland, Andrew M.
    Woods, Ryan
    Metjian, Ara
    Park, Yara A.
    de Ridder, Gustaaf
    Gibson, Briana
    Kasthuri, Raj S.
    Liles, Darla K.
    Akwaa, Frank
    Clover, Todd
    Kreuziger, Lisa Baumann
    Sridharan, Meera
    Go, Ronald S.
    Mccrae, Keith R.
    Upreti, Harsh Vardhan
    Gangaraju, Radhika
    Kocher, Nicole K.
    Zheng, X. Long
    Raval, Jay S.
    Masias, Camila
    Cataland, Spero R.
    Johnson, Andrew D.
    Davis, Elizabeth
    Evans, Michael D.
    Mazepa, Marshall
    Lim, Ming Y.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (03)
  • [49] Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura
    Truma, Addolorata
    Mancini, Ilaria
    Agosti, Pasquale
    Artoni, Andrea
    Giannotta, Juri Alessandro
    Ferrari, Barbara
    De Leo, Pasqualina
    Peyvandi, Flora
    THROMBOSIS RESEARCH, 2024, 243
  • [50] Hematuria due to immune-mediated thrombocytopenic purpura
    Masood, S
    Gontero, P
    Mufti, GR
    UROLOGIA INTERNATIONALIS, 2001, 67 (01) : 80 - 81